作者
Barbara Eichhorst, Carsten Niemann, Arnon P Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria BL Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus HJ Van Oers, Christian H Geisler, Stephan Stilgenbauer, Michael Hallek
发表日期
2021/11/23
期刊
Blood
卷号
138
页码范围
71
出版商
Content Repository Only!
简介
Background:
For fit CLL patients (pts), continuous BTK inhibitor treatment is replacing CIT as standard of care in frontline setting, particularly in pts with unfavorable prognostic factors. The time limited combinations venetoclax plus obinutuzumab (GVe) and venetoclax plus rituximab (RVe) have produced high rates of undetectable minimal residual disease (uMRD), which strongly associates with long progression-free survival (PFS) both in frontline and relapsed setting. For frontline therapy GVe is approved in this setting based on data from the CLL14 trial in an unfit population. However, data from a fit cohort are not yet available. The GAIA (CLL13) trial evaluated the efficacy and safety of three Ven+CD20 antibody-based regimens in comparison to CIT as a frontline treatment for fit pts with CLL and without TP53 mutation/deletion.
Methods:
Treatment-naïve fit (CIRS ≤6, normal creatinine clearance with ≥ 70ml/min …
学术搜索中的文章
B Eichhorst, C Niemann, AP Kater, M Fürstenau… - Blood, 2021